Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Moleculin Biotech (NASDAQ:MBRX) to a sell rating in a research note published on Wednesday.

Several other research firms have also recently weighed in on MBRX. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Moleculin Biotech in a report on Monday, March 24th. Maxim Group raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Tuesday.

Moleculin Biotech Price Performance

NASDAQ:MBRX opened at $1.04 on Wednesday. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $6.09. The stock has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.98.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.